Publications & Presentations
Transparency is a fundamental principle of the operations of the CBER Surveillance Program including the BEST Initiative, Sentinel System, CMS collaboration, and others. Knowledge acquired from the surveillance activities is placed in the public domain. To accomplish this aim, information concerning surveillance activities will be made available on the BEST website and other locations when appropriate.
Most Recent Publications & Presentations Assessments
Title
Date
Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databases
FDA BEST Lancet 2022 (pdf)
- Lancet 2022 399 2191 99 Supplementary appendix (pdf)
- Lancet Commentary (pdf)
- FDA BEST Lancet 2022-All Files (zip)
Show more +
This publication also includes a supplementary appendix and commentary.
06/11/2022
Vaccine exposure during pregnancy among privately and publicly insured women in the United States, 2016–2018
10/01/2021
Acute myocardial infarction: Development and application of an ICD-10-CM-based algorithm to a large U.S. healthcare claims-based database
journal pone 0253580 (pdf)
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0253580
07/01/2021
An FDA-CBER Update on Surveillance, Epidemiology and Risk Management Approaches for Biologics
01/29/2020
DIA PV and Risk Management Strategies Conference
Biologics Effectiveness and Safety (BEST) Initiative: Sentinel Public Meeting 2019
04/03/2019
Sentinel Public Meeting 2019
Biologics Effectiveness and Safety (BEST) Initiative: First Year
10/12/2018
OHDSI Symposium 2018